Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogenic AD-MSC Transplantation for Refractory FSGS
NCT02382874Phase 1Unknown
- Sponsor
- Royan Institute
- Start
- May 2015
- Primary completion
- Jun 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adipose derived mesenchymal stromal cells in focal segmental glomerulosclerosis (FSGS), sponsored by Royan Institute. Primary endpoints: Liver function at 2 weeks, Serum creatinine at 2 weeks and 1 more. Status: unknown.
02
Drugs
adipose derived mesenchymal stromal cells
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT02382874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02382874.